Using artificial intelligence to diagnose a range of diseases , Sophia Genetics , a Cambridge - based start - up and genetics testing company , has become the world 's largest provider for molecular diagnostics . Mike Lynch , whose firm Invoke Capital has invested $ 18 million , said that other companies “ desperately struggle to catch up . ” Using and analysing data from 100 hospitals , the company will diagnose over 80,000 diseases in 2020 . This data - rich ‘ precision medicine , ’ results in a faster and more accurate diagnosis , which in turn will lead to a specific , comprehensive treatment plan .
Using artificial intelligence to diagnose a range of diseases, Sophia Genetics, a Cambridge-based start-up and genetics testing company, has become the world's largest network for molecular diagnostics. Mike Lynch, whose firm Invoke Capital has invested $18m, said that other companies “will struggle to catch up.” Using and analysing data from 100 hospitals, the company will diagnose over 80,000 patients in 2016. This data-rich ‘precision medicine,’ results in a faster and more accurate diagnosis, which in turn will lead to a specific, tailored treatment plan.